Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
Busatto
G F
GF
Pilowsky
L S
LS
Ell
P J
PJ
Costa
D C
DC
Verhoeff
N P
NP
Kerwin
R W
RW
D000328:Adult; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001549:Benzamides / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects*; D001931:Brain Mapping; D003287:Contrast Media; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D007457:Iodine Radioisotopes; D007555:Isoxazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010880:Piperidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000502:physiology; D018967:Risperidone; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon
D014150:Antipsychotic Agents; D001549:Benzamides; D003287:Contrast Media; D065127:Dopamine D2 Receptor Antagonists; D007457:Iodine Radioisotopes; D007555:Isoxazoles; D010880:Piperidines; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D018967:Risperidone